Luigi La Corte Named Chief Financial Officer at Galderma
Galderma has announced the appointment of a new Chief Financial Officer, reinforcing its financial leadership and long-term growth strategy.
Punita Thakur 
Luigi La Corte Named Chief Financial Officer at Galderma
Galderma has announced the appointment of a new Chief Financial Officer (CFO), strengthening its executive leadership team as the company advances its global growth and financial strategy.
Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization.
Galderma has announced the appointment of a new Chief Financial Officer (CFO), strengthening its executive leadership team as the company advances its global growth and financial strategy.
The newly appointed CFO will oversee the company’s global finance operations, including financial planning, risk management, reporting, and capital allocation.
The leadership move reflects Galderma’s continued focus on financial discipline, operational efficiency, and long-term value creation.
As a leading dermatology-focused pharmaceutical company, Galderma operates in an increasingly dynamic global healthcare environment. Strengthening financial leadership is critical to supporting strategic investments, research and development initiatives, and international market expansion.
The appointment comes at a time when pharmaceutical and healthcare companies are prioritizing robust financial governance to navigate evolving regulatory frameworks and competitive pressures. With the new CFO in place, Galderma aims to further enhance financial oversight, support innovation pipelines, and drive sustainable growth across its global operations.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story
